Consider Onstryv Another MAO-B Inhibitor for Parkinson's

Onstryv (ON-striv, safinamide) will be a new add-on for Parkinson's disease.

Think of Onstryv as similar to selegiline or rasagiline (Azilect).

These selective MAO-B inhibitors prevent dopamine breakdown to reduce "off-time"...when carbidopa/levodopa wears off and symptoms worsen.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote